The healthcare industry’s most influential investment conference is almost here, are you ready? Every January, the J.P. Morgan Healthcare Conference sets the tone for the year ahead, shaping strategies, sparking partnerships, and driving investment decisions across the life sciences sector. To help you stay ahead, our expert analysts have created the #JPM2026 Preview Report, packed […]
Share:
Every January, the J.P. Morgan Healthcare Conference sets the tone for the year ahead, shaping strategies, sparking partnerships, and driving investment decisions across the life sciences sector.
To help you stay ahead, our expert analysts have created the #JPM2026 Preview Report, packed with insights you won’t want to miss.
By 2032, the global pharmaceutical market is forecast to reach almost $1.9tn. Inside the innovations, dealmaking, and portfolio strategies transforming the global biopharma pipeline.
Expect discussions on AI-driven drug discovery, cross-border biotech partnerships, and the evolving competitive landscape in high-growth therapeutic areas such as immunology, oncology, neuroscience, and rare diseases. Companies will also spotlight lifecycle management strategies and capital allocation priorities.
The conference provides early visibility into late-stage assets, regulatory catalysts, and emerging modalities like RNAi, gene editing, and antibody-drug conjugates. These insights help teams benchmark competitive positioning, identify gaps in therapeutic coverage, and align investment priorities with market trends.
Immunology, oncology, and metabolic disorders remain top targets, alongside rare diseases and advanced platforms such as cell and gene therapy. Companies are actively seeking assets that complement existing franchises or enable entry into high-value markets with unmet medical needs.
